Dr. Gaston De Serres is an epidemiologist practitioner at the l’Institut national de santé publique du Québec and a regular researcher in the Infectious and Immune Disease Axis at the CHU de Québec-Laval University. He is a full professor in epidemiology in the Department of social and preventive medicine at Laval University where he has been teaching since 1997. He is chief physician of the scientific immunization group (SIG) of the Institut national de santé publique du Québec and an active member of the Comité sur l’immunisation du Québec (CIQ).

Dr. De Serre works on the control and prevention of infectious diseases, with a focus on diseases that are avoidable through vaccination and on respiratory diseases. His research work is on the epidemiology of diseases that are preventable through vaccination and the efficacy of vaccinations used in routine programs, and in particular, on the efficacy of the influenza vaccine.

2400, avenue d'Estimauville, 3e étage
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6274+1 418-666-2776
gaston.de-serres@crchudeq... Gaston.DeSerres@inspq.qc....

Latest news

420 entries « ‹ 1 of 42 › »

Dzieciolowska S, Charest H, Roy T, Fafard J, Carazo S, Levade I, Longtin J, Parkes L, Beaulac SN, Villeneuve J, Savard P, Corbeil J, De Serres G, Longtin Y

Timing and Predictors of Loss of Infectivity Among Healthcare Workers With Mild Primary and Recurrent COVID-19: A Prospective Observational Cohort Study

Journal Article

Clin Infect Dis, 78 (3), 2024.

Abstract | Links:

Razafimandimby H, Sauvageau C, Ouakki M, Carazo S, Skowronski DM, De Serres G

Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023

Journal Article

Pediatr Infect Dis J, 43 (1), 2024.

Abstract | Links:

Mésidor M, Liu Y, Talbot D, Skowronski DM, De Serres G, Merckx J, Koushik A, Tadrous M, Carazo S, Jiang C, Schnitzer ME

Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review

Journal Article

Vaccine, 42 (5), 2024.

Abstract | Links:

Naveed Z, Chu C, Tadrous M, Veroniki AA, Li J, Rouleau I, Febriani Y, Calzavara A, Buchan SA, Nasreen S, Schwartz KL, Wilton J, Seo CY, Thampi N, Wilson SE, Naus M, De Serres G, Janjua NZ, Kwong JC,

A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection

Journal Article

Heliyon, 10 (5), 2024.

Abstract | Links:

Brillant-Marquis F, Proulx É, Ratnarajah K, Lavoie A, Gauthier A, Gagnon R, Boursiquot JN, Verreault N, Marois L, Bédard MA, Boivin M, Bédard PM, Ouakki M, De Serres G, Drolet JP

Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults

Journal Article

J Allergy Clin Immunol Pract, 12 (2), 2024.

Abstract | Links:

Halvorson T, Ivison S, Huang Q, Ladua G, Yotis DM, Mannar D, Subramaniam S, Ferreira VH, Kumar D, Belga S, Levings MK,

SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain

Journal Article

Transplantation, 108 (4), 2024.

Abstract | Links:

Soe P, Wong H, Naus M, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, Isenor JE, Marty K, De Serres G, Valiquette L, McGeer A, Bettinger JA,

mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network

Journal Article

Vaccine, 42 (18), 2024.

Abstract | Links:

Carazo S, Guay CA, Skowronski DM, Amini R, Charest H, De Serres G, Gilca R

Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012-2013 to 2018-2019 Seasons, Quebec, Canada

Journal Article

Clin Infect Dis, 78 (3), 2024.

Abstract | Links:

Brousseau N, Carazo S, Febriani Y, Padet L, Hegg-Deloye S, Cadieux G, Bergeron G, Fafard J, Charest H, Lambert G, Talbot D, Longtin J, Dumont-Blais A, Bastien S, Dalpé V, Minot PH, De Serres G, Skowronski DM

Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk

Journal Article

Clin Infect Dis, 78 (2), 2024.

Abstract | Links:

Charland K, Pierce L, Saucier A, Hamelin MÈ, Barbosa Da Torre M, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C, Zinszer K

Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study

Journal Article

Epidemiol Infect, 152 , 2024.

Abstract | Links:

420 entries « ‹ 1 of 42 › »
Signaler des ajouts ou des modifications

Active projects

  • Fréquence et séquelles fonctionnelles du syndrome post-COVID-19 chez les travailleurs de la santé , from 2023-03-02 to 2025-07-31
  • SI07 QC03(Combining studies SI03 and SI05), Optimizing the clinical management of patients with contraindication to vaccination and those with adverse events following immunization ... in the Special Immunization Clinic Network, from 2023-04-01 to 2025-03-31
  • The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2025-09-30

Recently finished projects

  • (SI03 QC03) Special Immunization Clinic Network (SIC) to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination ..., from 2019-04-01 to 2024-03-31
  • Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 Vaccine Post-Market Studies, from 2020-12-01 to 2023-06-30
  • CV07 QC03 Canadian National Vaccine Safety (CANVAS) network: Surveillance of Adverse Events Following Immunization among children and adults Immunized with the COVID-19 Vaccine, from 2021-04-01 to 2023-09-30
  • Enquête sérologique chez les travailleurs de la santé qui rapportent n’avoir jamais fait la COVID-19 depuis le début de la pandémie, from 2023-04-20 to 2023-12-31
  • HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
  • Prize 202203PJT - The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context, from 2022-10-01 to 2023-03-31
  • SI05 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-11-01 to 2024-03-31
  • SI06 QC03, Optimizing the clinical management of patients with adverse events following COVID-19 vaccination and potential contraindications to vaccination in the Special Immunization Clinic Network, from 2021-04-01 to 2023-10-31
Data provided by the Université Laval research projects registery